BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Medium (6M)
Nirmal Bang Recommends 'Buy' On Sun Pharmaceutical Industries
According to Nirmal Bang, Sun Pharmaceutical Industries' domestic business should continue to grow on the back of strength in chronic segment. The company's domestic portfolio has a low concentration risk as its top 10 brands contribute around 18 per cent to sales in India, the brokerage adds.